RxDoctor Payments Data

Vidyashankar Revan, MD

Allergy & Immunology · Wilmington, OHNPI 1194882571

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Novartis accounts for 61.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $5,384 and has fallen 83.4% since, to $892 in 2025.

$8,139in general payments, 2019–2025

Across 138 payments — averaging $58.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5K
  • AstraZeneca$809
  • GSK$787
  • Sanofi$559
  • Regeneron Healthcare Solutions, Inc.$430
  • Optinose US, Inc.$157
  • plus $392 from 9 others

What the payments were for

  • Consulting fees$4,75058%
  • Food & beverage$3,34041%
  • Education$491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,139 in reported general payments places this provider in the 70th percentile of 128 allergy & immunology providers in Ohio.

See all allergy & immunology providers in Ohio

Medicare billing

Part B allowed, 2024
$56,944
Medicare patients
130
Services billed
5,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab11$42,668
Arnuity ElliptaFluticasone Furoate82$23,997
SymbicortBudesonide/Formoterol Fumarate26$13,106
Fluticasone Propionate HfaFluticasone Propionate39$8,989
DuleraMometasone/Formoterol17$8,834
Epinephrine47$8,343
Breo ElliptaFluticasone/Vilanterol17$8,297
Qvar RedihalerBeclomethasone Dipropionate23$5,137
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate38$3,381
Fluticasone Propionate206$2,514
BreynaBudesonide/Formoterol Fumarate17$2,418
Albuterol Sulfate HfaAlbuterol Sulfate83$2,169
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$1,352
Montelukast Sodium123$1,079
Azelastine Hcl48$1,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta, Breo Ellipta$787$32,29499 claims
AstraZenecaSymbicort$809$13,10626 claims
Hikma Pharmaceuticals USAEpinephrine$46$8,34347 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$24$5,13723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 allergy & immunology providers in Ohio.

Other allergy & immunology in Wilmington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →